{"id":"AGY-FED-HEALTH-OTHER-009","kind":"order","level":"federal","jurisdiction":"United States (federal); Drug Enforcement Administration, Diversion Control Division","state":"","metro":"","industry":"","agency":"FED-HEALTH-OTHER","eco":"","issuer":"Drug Enforcement Administration, Diversion Control Division (with the HHS Secretary\u0027s designation of Mar. 16, 2020)","authority":"21 U.S.C. 802(54)(D) (telemedicine during a section 319 public health emergency, as designated by the Secretary with the concurrence of the Administrator); 21 U.S.C. 829(e) (Ryan Haight Act)","instrument":"DEA-DC-016, COVID-19 Information Page: Telemedicine (designation that the section 802(54)(D) telemedicine allowance applies to all schedule II-V controlled substances in all areas of the United States)","title":"Use of Telemedicine While Providing Medication Assisted Treatment / COVID-19 Telemedicine (updated)","dateIssued":"2020-03-16","effective":"2020-03-16","end":"Extended past the PHE by 88 Fed. Reg. 30037 (May 10, 2023) and successor temporary rules","startDate":"2020-03-16","endDate":"2023-05-10","quarters":["2020Q2","2020Q3","2020Q4","2021Q1","2021Q2","2021Q3"],"types":["HC","TELE","OTHER"],"addressees":["DEA-registered practitioners","pharmacies"],"clause":"On March 16, 2020, the Secretary, with the concurrence of the Acting DEA Administrator, designated that the telemedicine allowance under section 802(54)(D) applies to all schedule II-V controlled substances in all areas of the United States.... Provided the practitioner satisfies the above requirements, the practitioner may issue the prescription using any of the methods of prescribing currently available and in the manner set forth in the DEA regulations.","enforcement":"Prescriptions outside the allowance remain unlawful under 21 U.S.C. 829(e) and 841-843","functions":["TM telehealth","CL clinical intake without in-person evaluation","PR procedures and visits","CB patients"],"notes":"The controlled-substance half of the compelled telehealth substitute; reached every prescribing practice, behavioral-health provider, hospital and pharmacy.","sourceUrl":"https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-016)%20CoronaVirus%20(Telemedicine)%20Updated.pdf","snapshot":"","fileExists":true,"fileBytes":100356,"grade":"primary","character":"","description":"","collection":"AGY-FED-HEALTH-OTHER","url":"/library/AGY-FED-HEALTH-OTHER-009","exhibitUrl":"/exhibit/AGY-FED-HEALTH-OTHER-009","citation":"Drug Enforcement Administration, Diversion Control Division (with the HHS Secretary\u0027s designation of Mar. 16, 2020), DEA-DC-016, COVID-19 Information Page: Telemedicine (designation that the section 802(54)(D) telemedicine allowance applies to all schedule II-V controlled substances in all areas of the United States) (Mar. 16, 2020) (Ex. AGY-FED-HEALTH-OTHER-009)","stateName":"","related":[]}